Genelux Corporation (NasdaqCM: GNLX)
Health Care · Biotechnology · US
$2.55
-0.59% today · -49.5% 1Y
Genelux Corporation (NasdaqCM: GNLX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $114.72M and employs 26 people.
Over the last twelve months the share price has lost 49.5%, trading between 2.29 and 8.54.
Tweenvest scores Genelux Corporation across four factors: quality 46/100, value 41/100. Its strongest factor is quality.
GNLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $114.72M
- Revenue (TTM)
- $8.00K
- P/E
- —
- EPS
- -0.86
- Dividend yield
- —
- Beta (5Y)
- 0.58
- 52-week high
- $8.54
- 52-week low
- $2.29
- Avg volume (3M)
- —
- Shares outstanding
- 44.81M
- Employees
- 26
- Next earnings
- —
About Genelux Corporation
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
- ISIN
- US36870H1032
- Founded
- 2001
- Listed since
- Jan 26, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Coya Therapeutics, Inc.NasdaqCM: COYA | $116.12M | $4.81 | -2.83% |
| enGene Therapeutics Inc.NasdaqCM: ENGN | $115.94M | $1.70 | -1.73% |
| 4basebio PLCAIM: 4BB | $115.66M | £5.63 | 0.00% |
| PMV Pharmaceuticals, Inc.NasdaqGS: PMVP | $114.78M | $1.41 | -7.24% |
| Unicycive Therapeutics, Inc.NasdaqCM: UNCY | $114.49M | $4.05 | -1.46% |
| Quantum Cyber N.V.NasdaqCM: QUCY | $113.49M | $1.03 | -23.70% |
| Hamlet BioPharma AB (publ)XSAT: HAMLET B | $113.40M | Skr6.08 | +1.50% |
| Humacyte, Inc.NasdaqGS: HUMA | $112.59M | $0.39 | -3.87% |
Figures last refreshed Oct 11, 2026.